Company profile for MS Pharma

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

The Sukhtian Group has agreed to set up a new entity called MS Pharma, which consolidates El Kendi, UPM and Beit Jala and their affiliates MS Pharma aims at establishing one of the leading pharmaceutical regional groups in MENA region and pharmaceutically emerging markets within ten years with focus on the highly branded emerging markets. MS Pharma is dynamic and diverse and, at the same time, adheres to a common set of value...
The Sukhtian Group has agreed to set up a new entity called MS Pharma, which consolidates El Kendi, UPM and Beit Jala and their affiliates MS Pharma aims at establishing one of the leading pharmaceutical regional groups in MENA region and pharmaceutically emerging markets within ten years with focus on the highly branded emerging markets. MS Pharma is dynamic and diverse and, at the same time, adheres to a common set of values and vision. We plan to continue leading the pharmaceutical industry by remaining diligently committed to our patients. New management structure is split between strategic and operational functions. Strategic management team is comprised of current El Kendi, UPM and Beit Jala employees as well as new hires.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Jordan
Address
Address
Sahab – King Abdullah Industrial city P.O Box 12 Amman 11512
Telephone
Telephone
962 6 5827999
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20250902492755/en/Polpharma-Biologics-and-MS-Pharma-Sign-Licensing-Agreements-for-Proposed-Vedolizumab-PB016-Ocrelizumab-PB018-and-Guselkumab-PB019-Biosimilars

BUSINESSWIRE
02 Sep 2025

https://www.prnewswire.com/news-releases/ms-pharma-establishes-menas-first-biologics-manufacturing-hub-in-saudi-arabia-advancing-regional-leadership-and-global-partnerships-302539994.html

PR NEWSWIRE
27 Aug 2025

https://www.businesswire.com/news/home/20250805355377/en/Kashiv-BioSciences-and-MS-Pharma-Enter-into-MENA-License-and-Supply-Agreement-for-ADL-018-Biosimilar-Candidate-to-XOLAIR-bOmalizumab

BUSINESSWIRE
05 Aug 2025

https://www.pharmiweb.com/press-release/2024-05-15/ms-pharma-becomes-partner-for-the-commercialization-of-fyb203-formycon-s-biosimilar-candidate-to-ey

PHARMIWEB
14 May 2024
Neopharm Labs Acquires MS Pharma
Neopharm Labs Acquires MS Pharma

28 Mar 2023

// CONTRACT PHARMA

https://www.contractpharma.com/contents/view_breaking-news/2023-03-27/neopharm-labs-acquires-ms-pharma/?widget=listSection

CONTRACT PHARMA
28 Mar 2023
MS Pharma acquires Genepharm, expands chronic disease portfolio
MS Pharma acquires Genepharm, expands chronic disease portfolio

23 Apr 2019

// Vassia Barba IN-PHARMANECHNOLOGIST

https://www.in-pharmatechnologist.com/Article/2019/04/23/MS-Pharma-acquires-Genepharm

Vassia Barba IN-PHARMANECHNOLOGIST
23 Apr 2019

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty